Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Lurbinectedin was evaluated in a multicenter, open-label, Basket phase 2 study in nine cohorts of patients with different difficult-to-treat tumor types to establish the proof of concept for clinical development [1–5]. Based on the results observed in a cohort of 105 patients with pretreated small cell lung cancer (SCLC) [1], lurbinectedin was approved first in the United States [6] and later in several other countries worldwide. Furthermore, and based on these same results, the European Society of Medical Oncology (ESMO) and the US National Comprehensive Cancer Network (NCCN) guidelines incorporated lurbinectedin as an option for the second-line treatment of SCLC patients [7,8].